These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
786 related articles for article (PubMed ID: 23146280)
1. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Linardou H; Kalogeras KT; Kronenwett R; Kouvatseas G; Wirtz RM; Zagouri F; Gogas H; Christodoulou C; Koutras AK; Samantas E; Pectasides D; Bafaloukos D; Fountzilas G Breast Cancer Res; 2012 Nov; 14(6):R145. PubMed ID: 23146280 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. Linardou H; Kalogeras KT; Kronenwett R; Alexopoulou Z; Wirtz RM; Zagouri F; Scopa CD; Gogas H; Petraki K; Christodoulou C; Pavlakis K; Koutras AK; Samantas E; Patsea H; Pectasides D; Bafaloukos D; Fountzilas G Anticancer Res; 2015 Jul; 35(7):4023-36. PubMed ID: 26124351 [TBL] [Abstract][Full Text] [Related]
3. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. Fountzilas G; Dafni U; Bobos M; Batistatou A; Kotoula V; Trihia H; Malamou-Mitsi V; Miliaras S; Chrisafi S; Papadopoulos S; Sotiropoulou M; Filippidis T; Gogas H; Koletsa T; Bafaloukos D; Televantou D; Kalogeras KT; Pectasides D; Skarlos DV; Koutras A; Dimopoulos MA PLoS One; 2012; 7(6):e37946. PubMed ID: 22679488 [TBL] [Abstract][Full Text] [Related]
4. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363 [TBL] [Abstract][Full Text] [Related]
5. Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. Goussia A; Simou N; Zagouri F; Manousou K; Lazaridis G; Gogas H; Koutras A; Sotiropoulou M; Pentheroudakis G; Bafaloukos D; Markopoulos C; Patsea H; Christodoulou C; Papakostas P; Zaramboukas T; Samantas E; Kosmidis P; Venizelos V; Karanikiotis C; Papatsibas G; Xepapadakis G; Kalogeras KT; Bamia C; Dimopoulos MA; Malamou-Mitsi V; Fountzilas G; Batistatou A PLoS One; 2018; 13(7):e0200302. PubMed ID: 30063723 [TBL] [Abstract][Full Text] [Related]
6. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029 [TBL] [Abstract][Full Text] [Related]
7. Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Razis E; Kalogeras KT; Kotoula V; Eleftheraki AG; Nikitas N; Kronenwett R; Timotheadou E; Christodoulou C; Pectasides D; Gogas H; Wirtz RM; Makatsoris T; Bafaloukos D; Aravantinos G; Televantou D; Pavlidis N; Fountzilas G Clin Breast Cancer; 2012 Jun; 12(3):183-93. PubMed ID: 22607768 [TBL] [Abstract][Full Text] [Related]
8. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of RACGAP1 mRNA expression in high-risk early breast cancer: a study in primary tumors of breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Pliarchopoulou K; Kalogeras KT; Kronenwett R; Wirtz RM; Eleftheraki AG; Batistatou A; Bobos M; Soupos N; Polychronidou G; Gogas H; Samantas E; Christodoulou C; Makatsoris T; Pavlidis N; Pectasides D; Fountzilas G Cancer Chemother Pharmacol; 2013 Jan; 71(1):245-55. PubMed ID: 23096218 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Koutras AK; Kalogeras KT; Dimopoulos MA; Wirtz RM; Dafni U; Briasoulis E; Pectasides D; Gogas H; Christodoulou C; Aravantinos G; Zografos G; Timotheadou E; Papakostas P; Linardou H; Razis E; Economopoulos T; Kalofonos HP; Fountzilas G; Br J Cancer; 2008 Dec; 99(11):1775-85. PubMed ID: 18985033 [TBL] [Abstract][Full Text] [Related]
11. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. Psyrri A; Kalogeras KT; Wirtz RM; Kouvatseas G; Karayannopoulou G; Goussia A; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Koutras A; Lazaridis G; Christodoulou C; Pentheroudakis G; Economopoulou P; Laskarakis A; Arapantoni-Dadioti P; Batistatou A; Sotiropoulou M; Aravantinos G; Papakostas P; Kosmidis P; Pectasides D; Fountzilas G J Transl Med; 2017 Feb; 15(1):30. PubMed ID: 28193231 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. Koutras A; Kalogeras KT; Wirtz RM; Alexopoulou Z; Bobos M; Zagouri F; Veltrup E; Timotheadou E; Gogas H; Pentheroudakis G; Pisanidis N; Magkou C; Christodoulou C; Bafaloukos D; Papakostas P; Aravantinos G; Pectasides D; Kalofonos HP; Fountzilas G J Transl Med; 2015 May; 13():171. PubMed ID: 26021752 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. Psyrri A; Kalogeras KT; Kronenwett R; Wirtz RM; Batistatou A; Bournakis E; Timotheadou E; Gogas H; Aravantinos G; Christodoulou C; Makatsoris T; Linardou H; Pectasides D; Pavlidis N; Economopoulos T; Fountzilas G Ann Oncol; 2012 Jun; 23(6):1422-7. PubMed ID: 22056852 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy. Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732 [TBL] [Abstract][Full Text] [Related]
15. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM; J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968 [TBL] [Abstract][Full Text] [Related]
17. Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. Bartlett JM; Munro A; Cameron DA; Thomas J; Prescott R; Twelves CJ J Clin Oncol; 2008 Nov; 26(31):5027-35. PubMed ID: 18768436 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Kostopoulos I; Arapantoni-Dadioti P; Gogas H; Papadopoulos S; Malamou-Mitsi V; Scopa CD; Markaki S; Karagianni E; Kyriakou V; Margariti A; Kyrkou E; Pavlakis K; Zaramboukas T; Skordalaki A; Bourli A; Markopoulos C; Pectasides D; Dimopoulos MA; Skarlos D; Fountzilas G Breast Cancer Res Treat; 2006 Apr; 96(3):251-61. PubMed ID: 16538542 [TBL] [Abstract][Full Text] [Related]
19. The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. Jensen MB; Lænkholm AV; Nielsen TO; Eriksen JO; Wehn P; Hood T; Ram N; Buckingham W; Ferree S; Ejlertsen B Breast Cancer Res; 2018 Jul; 20(1):79. PubMed ID: 30053900 [TBL] [Abstract][Full Text] [Related]
20. Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. Schneider BP; Gray RJ; Radovich M; Shen F; Vance G; Li L; Jiang G; Miller KD; Gralow JR; Dickler MN; Cobleigh MA; Perez EA; Shenkier TN; Vang Nielsen K; Müller S; Thor A; Sledge GW; Sparano JA; Davidson NE; Badve SS Clin Cancer Res; 2013 Mar; 19(5):1281-9. PubMed ID: 23340303 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]